Atlas Trials

Significant Bleeding Risk

2 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Significant Bleeding Risk

RecordFirmDate
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure (NCT06429787)Octapharma2025-02-14
Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk. (NCT02740335)Octapharma2017-06-08

Track Significant Bleeding Risk automatically

Every clearance here is in the API, with alerts when new ones post.